Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 13 | 2017 | 117 | 1.380 |
Why?
|
| Salivary Gland Neoplasms | 3 | 2017 | 12 | 1.300 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2017 | 7 | 1.190 |
Why?
|
| Receptors, Chemokine | 1 | 2016 | 9 | 0.580 |
Why?
|
| Chemokines | 1 | 2016 | 35 | 0.570 |
Why?
|
| Esophageal Stenosis | 3 | 2011 | 6 | 0.570 |
Why?
|
| Thyroid Neoplasms | 2 | 2008 | 28 | 0.560 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2016 | 142 | 0.540 |
Why?
|
| Parathyroid Hormone | 2 | 2014 | 38 | 0.530 |
Why?
|
| MicroRNAs | 1 | 2017 | 173 | 0.520 |
Why?
|
| Hypercalcemia | 1 | 2014 | 8 | 0.490 |
Why?
|
| Parathyroid Neoplasms | 1 | 2014 | 7 | 0.490 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2014 | 8 | 0.480 |
Why?
|
| Adenoma | 1 | 2014 | 35 | 0.470 |
Why?
|
| Thyroidectomy | 2 | 2011 | 14 | 0.470 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2006 | 401 | 0.450 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 384 | 0.430 |
Why?
|
| Hypocalcemia | 1 | 2011 | 8 | 0.410 |
Why?
|
| Early Diagnosis | 1 | 2011 | 61 | 0.410 |
Why?
|
| Plicamycin | 1 | 2011 | 1 | 0.410 |
Why?
|
| Burns, Chemical | 1 | 2011 | 7 | 0.400 |
Why?
|
| Drug-Eluting Stents | 1 | 2011 | 16 | 0.400 |
Why?
|
| Collagen | 1 | 2011 | 217 | 0.360 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2008 | 1 | 0.330 |
Why?
|
| Eosinophilia | 1 | 2008 | 16 | 0.320 |
Why?
|
| Smoking | 3 | 2016 | 427 | 0.310 |
Why?
|
| Salivary Glands | 3 | 2017 | 14 | 0.300 |
Why?
|
| Aged | 15 | 2016 | 9487 | 0.290 |
Why?
|
| Female | 20 | 2016 | 18164 | 0.280 |
Why?
|
| Humans | 26 | 2017 | 29093 | 0.280 |
Why?
|
| Submandibular Gland | 1 | 2005 | 4 | 0.270 |
Why?
|
| Hypopharynx | 1 | 2004 | 2 | 0.260 |
Why?
|
| Gastroscopy | 1 | 2004 | 9 | 0.260 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 680 | 0.250 |
Why?
|
| Laryngoscopy | 1 | 2004 | 39 | 0.250 |
Why?
|
| Treatment Outcome | 9 | 2016 | 3099 | 0.250 |
Why?
|
| Male | 17 | 2016 | 17807 | 0.250 |
Why?
|
| Ventilator Weaning | 1 | 2004 | 4 | 0.250 |
Why?
|
| Middle Aged | 16 | 2016 | 10829 | 0.240 |
Why?
|
| Carcinoma | 1 | 2005 | 87 | 0.240 |
Why?
|
| Pneumonia, Bacterial | 1 | 2004 | 31 | 0.240 |
Why?
|
| Cross Infection | 1 | 2004 | 46 | 0.240 |
Why?
|
| Clinical Protocols | 1 | 2004 | 95 | 0.240 |
Why?
|
| Neck Dissection | 4 | 2008 | 9 | 0.240 |
Why?
|
| Respiration, Artificial | 1 | 2004 | 96 | 0.230 |
Why?
|
| Combined Modality Therapy | 8 | 2014 | 525 | 0.220 |
Why?
|
| Taxoids | 5 | 2006 | 47 | 0.210 |
Why?
|
| Immunohistochemistry | 4 | 2014 | 519 | 0.200 |
Why?
|
| Calcium | 2 | 2014 | 296 | 0.190 |
Why?
|
| Paclitaxel | 3 | 2005 | 50 | 0.170 |
Why?
|
| Postoperative Complications | 2 | 2015 | 670 | 0.160 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2017 | 9 | 0.160 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2017 | 9 | 0.160 |
Why?
|
| Retrospective Studies | 6 | 2014 | 3111 | 0.150 |
Why?
|
| Micronutrients | 1 | 2017 | 15 | 0.150 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 118 | 0.140 |
Why?
|
| Plant Extracts | 1 | 2017 | 60 | 0.140 |
Why?
|
| Aged, 80 and over | 6 | 2016 | 3717 | 0.140 |
Why?
|
| Cesium Radioisotopes | 1 | 2015 | 5 | 0.140 |
Why?
|
| Gene Expression | 1 | 2017 | 332 | 0.140 |
Why?
|
| Gamma Rays | 1 | 2015 | 24 | 0.140 |
Why?
|
| Laryngeal Muscles | 1 | 2015 | 16 | 0.140 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2015 | 32 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 189 | 0.140 |
Why?
|
| Muscle Proteins | 1 | 2015 | 57 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 199 | 0.130 |
Why?
|
| Self Disclosure | 1 | 2015 | 23 | 0.130 |
Why?
|
| Muscular Atrophy | 1 | 2015 | 67 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2006 | 68 | 0.130 |
Why?
|
| Adult | 11 | 2016 | 8420 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 249 | 0.130 |
Why?
|
| Mucositis | 1 | 2014 | 8 | 0.130 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2014 | 13 | 0.120 |
Why?
|
| Alphapapillomavirus | 1 | 2014 | 9 | 0.120 |
Why?
|
| Parathyroidectomy | 1 | 2014 | 10 | 0.120 |
Why?
|
| Rare Diseases | 1 | 2014 | 20 | 0.120 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 89 | 0.120 |
Why?
|
| Salivary Glands, Minor | 1 | 2013 | 9 | 0.120 |
Why?
|
| Time Factors | 2 | 2011 | 2001 | 0.110 |
Why?
|
| Reference Values | 2 | 2011 | 224 | 0.110 |
Why?
|
| Thyroid Diseases | 1 | 2011 | 6 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2011 | 2108 | 0.100 |
Why?
|
| ROC Curve | 1 | 2011 | 149 | 0.100 |
Why?
|
| Mucous Membrane | 1 | 2011 | 20 | 0.100 |
Why?
|
| Carboplatin | 3 | 2006 | 40 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2006 | 163 | 0.100 |
Why?
|
| Administration, Topical | 1 | 2011 | 130 | 0.100 |
Why?
|
| Random Allocation | 1 | 2011 | 213 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2013 | 493 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 863 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 301 | 0.090 |
Why?
|
| Dilatation | 1 | 2010 | 9 | 0.090 |
Why?
|
| Neoplasm Staging | 4 | 2016 | 436 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 787 | 0.090 |
Why?
|
| Length of Stay | 2 | 2015 | 292 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2011 | 747 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2014 | 1305 | 0.080 |
Why?
|
| Sclerosis | 1 | 2008 | 10 | 0.080 |
Why?
|
| Cisplatin | 5 | 2006 | 69 | 0.080 |
Why?
|
| Fluorouracil | 5 | 2006 | 73 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 980 | 0.080 |
Why?
|
| Tissue Culture Techniques | 1 | 2007 | 40 | 0.070 |
Why?
|
| Rats | 1 | 2011 | 1604 | 0.070 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2006 | 1 | 0.070 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2006 | 7 | 0.070 |
Why?
|
| Deglutition Disorders | 1 | 2006 | 50 | 0.070 |
Why?
|
| Laryngeal Neoplasms | 1 | 2005 | 11 | 0.070 |
Why?
|
| Xerostomia | 1 | 2005 | 29 | 0.070 |
Why?
|
| Cotinine | 2 | 2015 | 45 | 0.070 |
Why?
|
| Animals | 3 | 2015 | 7297 | 0.060 |
Why?
|
| Fibrosis | 1 | 2005 | 102 | 0.060 |
Why?
|
| Pharyngeal Diseases | 1 | 2004 | 8 | 0.060 |
Why?
|
| Nasal Bone | 1 | 2004 | 3 | 0.060 |
Why?
|
| Constriction, Pathologic | 1 | 2004 | 41 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2016 | 1356 | 0.060 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2004 | 22 | 0.060 |
Why?
|
| Infection Control Practitioners | 1 | 2004 | 1 | 0.060 |
Why?
|
| Respiratory Therapy | 1 | 2004 | 4 | 0.060 |
Why?
|
| Incidence | 2 | 2006 | 1119 | 0.060 |
Why?
|
| Infection Control | 1 | 2004 | 21 | 0.060 |
Why?
|
| Fetus | 1 | 2004 | 78 | 0.060 |
Why?
|
| Injury Severity Score | 1 | 2004 | 115 | 0.060 |
Why?
|
| Age Distribution | 1 | 2004 | 198 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 2004 | 118 | 0.060 |
Why?
|
| Tissue Engineering | 2 | 2007 | 608 | 0.060 |
Why?
|
| Critical Care | 1 | 2004 | 114 | 0.060 |
Why?
|
| Hospital Mortality | 1 | 2004 | 186 | 0.060 |
Why?
|
| Risk Factors | 2 | 2015 | 3531 | 0.050 |
Why?
|
| Inflammation | 1 | 2005 | 507 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2015 | 281 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2015 | 2019 | 0.050 |
Why?
|
| Survival Rate | 3 | 2006 | 795 | 0.040 |
Why?
|
| Powders | 1 | 2017 | 8 | 0.040 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2017 | 13 | 0.040 |
Why?
|
| Phytotherapy | 1 | 2017 | 38 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 29 | 0.040 |
Why?
|
| Demography | 1 | 2016 | 104 | 0.040 |
Why?
|
| Antioxidants | 1 | 2017 | 114 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 46 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2015 | 21 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 501 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2006 | 156 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2017 | 170 | 0.030 |
Why?
|
| Mice | 2 | 2015 | 2368 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2014 | 74 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2007 | 799 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 281 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 711 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 726 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2014 | 208 | 0.030 |
Why?
|
| Prognosis | 2 | 2006 | 1362 | 0.020 |
Why?
|
| Eating | 1 | 2010 | 73 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 546 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 871 | 0.020 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2007 | 9 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2007 | 33 | 0.020 |
Why?
|
| Remission Induction | 1 | 2006 | 78 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2006 | 98 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2006 | 38 | 0.020 |
Why?
|
| Laryngectomy | 1 | 2005 | 3 | 0.020 |
Why?
|
| Aquaporin 5 | 1 | 2005 | 4 | 0.020 |
Why?
|
| Biodegradation, Environmental | 1 | 2005 | 4 | 0.020 |
Why?
|
| Aquaporins | 1 | 2005 | 5 | 0.020 |
Why?
|
| alpha-Amylases | 1 | 2005 | 4 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2005 | 43 | 0.020 |
Why?
|
| Keratins | 1 | 2005 | 36 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2005 | 118 | 0.020 |
Why?
|
| Aneuploidy | 1 | 2004 | 8 | 0.020 |
Why?
|
| Pregnancy Trimester, First | 1 | 2004 | 6 | 0.020 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2004 | 13 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2007 | 436 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 248 | 0.020 |
Why?
|
| Gestational Age | 1 | 2004 | 96 | 0.020 |
Why?
|
| Organoids | 1 | 2005 | 68 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2005 | 263 | 0.020 |
Why?
|
| Disease Progression | 1 | 2006 | 572 | 0.020 |
Why?
|
| Diet | 1 | 2006 | 354 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2005 | 256 | 0.010 |
Why?
|
| Leucovorin | 1 | 2003 | 20 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2003 | 21 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2003 | 14 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2003 | 18 | 0.010 |
Why?
|
| Phenotype | 1 | 2005 | 629 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2005 | 337 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2003 | 159 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 246 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2006 | 1687 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2003 | 440 | 0.010 |
Why?
|
| Pregnancy | 1 | 2004 | 815 | 0.010 |
Why?
|
| Quality of Life | 1 | 2006 | 816 | 0.010 |
Why?
|